News

French actor Pierre Deny, known for his role in the Netflix streaming series “Emily in Paris,” has died from amyotrophic lateral sclerosis (ALS) at age 69. “It is with deep emotion that we announce the passing of Pierre Deny, which occurred this Monday following a sudden and severe case of…

Living in areas with a moderate amount of green space appears to reduce the likelihood of developing amyotrophic lateral sclerosis (ALS) — but both very low and very high levels of greenness may increase the odds for different reasons, according to a study from Italy. The findings “may have…

There is an association between traumatic head injuries and amyotrophic lateral sclerosis (ALS), but the nature of this relationship remains unclear, according to a review and meta-analysis of published studies. People who had a history of a traumatic head injury were nearly 50% more likely than those without head…

AC Immune’s experimental imaging agent ACI-19626 continues to show a good safety profile and has shown promise for detecting toxic TDP-43 protein clumps in people with amyotrophic lateral sclerosis (ALS). That’s according to new data from an ongoing Phase 1 clinical trial (NCT06891716), in which the PET…

The APOE4 gene variant, an established genetic risk factor for Alzheimer’s disease, may also influence how toxic TDP-43 protein clumps spread in people with amyotrophic lateral sclerosis (ALS), a study suggested. Researchers found that people with ALS who carried the variant were significantly more likely to show TDP-43…

Outsee has been selected for a Discovery Award from the Longitude Prize on ALS to support the use of the company’s artificial intelligence (AI)-based platform and large-scale patient genomic data to identify new therapeutic targets for amyotrophic lateral sclerosis (ALS). The Longitude Prize on ALS is a £7.5…

Statins, medications designed to lower cholesterol, do not meaningfully alter the risk of death or disease progression in people with amyotrophic lateral sclerosis (ALS), according to a study. The researchers said the findings show that ALS itself should not influence doctors’ decisions about prescribing statins. Instead, statins should be…

Differences in the inflammatory activity of certain immune cells may explain why amyotrophic lateral sclerosis (ALS) progresses faster in some people than others, according to a study. The findings suggest that it may be possible to slow ALS progression by targeting specific inflammatory disease markers. “The intensity of spinal…

Neurizon Therapeutics has received ethics approval for an Australia-based Phase 1 clinical trial that will test an oral liquid formulation of NUZ-001, which the company is developing for amyotrophic lateral sclerosis (ALS), in healthy volunteers. A tablet version of NUZ-001 is being tested in a Phase 2/3 clinical…

An international team of scientists has developed an RNA-based experimental medicine that has the potential to reduce clumping of the TDP-43 protein, a key molecular feature of amyotrophic lateral sclerosis (ALS). The researchers determined, in precise molecular detail, how the RNA-based therapy interacts with the TDP-43 protein and showed…